Skip to content

Technology
Clinical Data
Pipeline
About
Media
Contact

Author: Sam Roberts

News Press

16/12/2024

ENEA-Tech Biomedical Foundation Invests €6m in BetaGlue® Therapeutics Bringing 2024 Funding Round Total to €24m

Technology
Clinical Data
Pipeline
About
Contact

Legal headquarters: Via della Moscova, 3 – 20121 Milan, Italy

YntraDose® is currently under development and is not approved for human use or sale.

© 2025 BetaGlue Therapeutics SpA. All rights reserved | TAX ID number: 06496571214

Privacy Policy
Cookie Policy
Corporate Governance